Results 131 to 140 of about 5,184 (154)

Carfilzomib/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022
Jan Kielstein, Jens Martens-Lobenhoffer, Bode-Böger Stefanie Margarethe   +2 more
exaly  

Nirmatrelvir/Ritonavir/Tacrolimus

Reactions Weekly
  +6 more sources

Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study

Journal of Medical Virology, 2023
Pinhua Pan, Furong Zeng, Guangtong Deng   +2 more
exaly  

Nirmatrelvir+ritonavir/tozinameran

Reactions Weekly, 2023
openaire   +1 more source

Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC–MS/MS and its pharmacokinetic application in healthy Chinese volunteers

Biomedical Chromatography, 2022
Chenxi Liu
exaly  

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy

Journal of Infection, 2022
Andrew Evans
exaly  

Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal

Open Forum Infectious Diseases, 2022
Kristin Mondy, , Alexander L Chu
exaly  

Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID‐19 patients: A systematic review and meta‐analysis

Journal of Medical Virology, 2023
Zhaoyan Chen, Fangyuan Tian
exaly  

Nirmatrelvir/ritonavir and pharmacovigilance data

The International Journal of Tuberculosis and Lung Disease
S, Lassan, M, Gocova, I, Solovic, T, Tesar, Z, Motesicka, M, Lassanova   +5 more
openaire   +2 more sources